GLP 1 News and Research

RSS

Older adults show interest in deprescribing, study reveals

More than 82% of Americans age 50 to 80 take one or more kinds of prescription medication, and 80% of them say they'd be open to stopping one or more of those drugs if their health care provider gave the green light, a new University of Michigan study shows.

24 Jul 2024

Why millions are trying FDA-authorized alternatives to big pharma’s weight loss drugs

Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself "at my ideal body weight," with his cholesterol below 200 for the first time in 20 years. "I feel fantastic," he said.

23 Jul 2024

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

The advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control.

23 Jul 2024

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

In a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders.

18 Jul 2024

Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes

Researchers found that adherence and persistence in T2D patients using oral semaglutide is similar to DPP-4i, but semaglutide users required fewer concurrent medications, indicating higher long-term efficacy.

16 Jul 2024

Harnessing brain proteins for enhanced diabetes and weight-loss drugs

A network of proteins found in the central nervous system could be harnessed to increase the effectiveness and reduce the side effects of popular diabetes and weight-loss drugs, according to new research from the University of Michigan.

15 Jul 2024

SH2B1 gene defends against obesity via the paraventricular hypothalamus

Obesity is a complicated condition, caused by a combination of genetics, the food environment, behavior, and other factors.

15 Jul 2024

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.

15 Jul 2024

AI analysis of Reddit reveals public interest in GLP-1 drugs for weight loss and mental health benefits

Researchers analyzed over 391,000 Reddit discussions using AI to study public perceptions of GLP-1 RAs, finding high interest in weight loss, side effects, and access issues, with mostly neutral-to-positive sentiment.

14 Jul 2024

Study reveals potential cognitive benefits of antidiabetic drugs

Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and Alzheimer's disease (AD) were significantly lower in patients treated with metformin and sodium glucose co-transporter-2 inhibitors (SGLT-2i) compared to other antidiabetic drugs.

12 Jul 2024

How lipoproteins shape your metabolic health

Study provides a comprehensive review of the lipoprotein pathway and its impact on healthy metabolism, highlighting the roles of HDL, LDL, and other lipoproteins in cardiovascular health and disease.

11 Jul 2024

Tirzepatide outperforms semaglutide in weight loss for overweight and obese adults

Tirzepatide leads to significantly greater weight loss than semaglutide in overweight or obese adults, with no significant difference in gastrointestinal adverse effects.

10 Jul 2024

Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease

New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes.

8 Jul 2024

Semaglutide linked to increased risk of severe eye condition NAION in new study

Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes and obesity.

8 Jul 2024

GLP-1 drugs found to lower cancer risk in diabetes patients

Research finds that GLP-1 receptor agonists significantly reduce the risk of 10 out of 13 obesity-associated cancers in type 2 diabetes patients compared to insulins, but show varied results against metformin.

8 Jul 2024

Natural compound found in olives can lower blood sugar levels and promote weight loss

Findings from a new mouse study suggest that elenolic acid, a natural compound found in olives, can lower blood sugar levels and promote weight loss.

29 Jun 2024

New study reveals how GLP-1 receptor agonists enhance preingestive fullness

GLP-1 receptor agonists promote the feeling of fullness before eating via neurons in the dorsomedial hypothalamus, according to a new study. The findings offer new insights into the neural pathways by which GLP-1 receptor agonists increase the feeling of fullness to prevent overconsumption of food, which is key in mitigating obesity. Glucagon-like-peptide-1 (GLP-1) plays an important role in signaling the feeling of fullness after eating.

27 Jun 2024

GLP 1 News and Research

Older adults show interest in deprescribing, study reveals

Why millions are trying FDA-authorized alternatives to big pharma’s weight loss drugs

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes

Harnessing brain proteins for enhanced diabetes and weight-loss drugs

SH2B1 gene defends against obesity via the paraventricular hypothalamus

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

AI analysis of Reddit reveals public interest in GLP-1 drugs for weight loss and mental health benefits

Study reveals potential cognitive benefits of antidiabetic drugs

How lipoproteins shape your metabolic health

Tirzepatide outperforms semaglutide in weight loss for overweight and obese adults

Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease

Semaglutide linked to increased risk of severe eye condition NAION in new study

GLP-1 drugs found to lower cancer risk in diabetes patients

Natural compound found in olives can lower blood sugar levels and promote weight loss

New study reveals how GLP-1 receptor agonists enhance preingestive fullness

Study reveals exercise and GLP-1 RA combination preserves bone health during weight loss

Differences in effectiveness among antihyperglycemic drugs on dementia risk identified in recent study

New drug tirzepatide significantly improves sleep apnea and weight loss

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News